<DOC>
	<DOCNO>NCT00041067</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Colony-stimulating factor , filgrastim , may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine trastuzumab docetaxel , vinorelbine , filgrastim treat woman stage IV breast cancer .</brief_summary>
	<brief_title>S0215 Trastuzumab , Docetaxel , Vinorelbine , Filgrastim Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 1-year survival woman HER2-positive stage IV breast cancer treat trastuzumab ( Herceptin ) , docetaxel , vinorelbine filgrastim ( G-CSF ) support . - Determine response rate ( complete partial , confirm unconfirmed ) subset patient measurable disease treat regimen . - Determine progression-free survival patient treat regimen . - Determine qualitative quantitative toxic effect regimen patient . - Obtain tissue block determination predictor response ( e.g. , beta-tubulin mutation ) microtubule interact agent patient population future study . OUTLINE : This pilot , multicenter study . Patients receive docetaxel IV 1 hour day 1 , filgrastim ( G-CSF ) subcutaneously day 2-21 , vinorelbine IV 6-10 minute day 8 15 , trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 . Courses repeat every 21 day absence disease progression unacceptable toxicity . If docetaxel vinorelbine discontinue due unacceptable toxicity , patient may continue receive trastuzumab . If trastuzumab discontinue due unacceptable toxicity , patient may continue receive chemotherapy G-CSF support . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 90 patient accrue study within 18-22.5 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast cancer Metastasis ipsilateral supraclavicular lymph node allow HER2positive fluorescence situ hybridization ( FISH ) immunohistochemistry 3+ staining confirm adjuvant metastatic set No effusion ascites site disease No primary metastatic brain central nervous system tumor Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal aspartate aminotransferase Alanine aminotranferease great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Not specify Cardiovascular : leave ventricular ejection fraction normal multigated radionuclide angiography echocardiogram ( patient receive prior anthracycline therapy ) No clinical evidence history cardiomyopathy Other : No preexist grade 2 great motor sensory peripheral neuropathy except abnormality due cancer No prior severe hypersensitivity reaction docetaxel drug formulate Polysorbate 80 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission No known sensitivity E. coliderived protein Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior chemotherapy Prior anthracycline adjuvant therapy allow No prior cumulative dose doxorubicin 360 mg/m^2 No prior cumulative dose epirubicin 720 mg/m^2 No 1 prior adjuvant neoadjuvant chemotherapy regimen primary disease No prior docetaxel No prior vinorelbine Prior paclitaxel allow Endocrine therapy : Prior hormonal therapy adjuvant therapy metastatic breast cancer allow No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy Surgery : At least 2 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>